Drug or technology
3 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval action for a Risk Evaluation and Mitigation Strategy (REMS) programme for oxymorphone hydrochloride extended-release tablets; this is a regulatory decision, not a clinical efficacy or safety study.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of REMS for oxymorphone hydrochloride; regulatory action only, not a clinical trial or efficacy study.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for oxymorphone hydrochloride REMS; regulatory action establishing risk mitigation strategy, not clinical efficacy data.